Variable | NO. (%) | P value | |||
---|---|---|---|---|---|
Training cohort | Internal validation cohort | External validation cohort | |||
Sex | < 0.001 | ||||
Female | 715(37.9) | 295(36.4) | 58(24.5) | ||
Male | 1173(62.1) | 515(63.6) | 179(75.5) | ||
Race | < 0.001 | ||||
White | 1210(64.1) | 506(62.5) | 0 | ||
Black | 191(10.1) | 96(11.8) | 0 | ||
Other | 487(25.8) | 208(25.7) | 237(100) | ||
Age, years | < 0.001 | ||||
≤ 80 | 1472(78.0) | 635(78.4) | 231(97.5) | ||
>80 | 416(22.0) | 175(21.6) | 6(2.5) | ||
Marital status | < 0.001 | ||||
Unmarried | 704(37.3) | 304(37.5) | 8(3.4) | ||
Married | 1184(62.7) | 506(62.5) | 229(96.6) | ||
Site | < 0.001 | ||||
Cardia | 503(26.6) | 195(24.1) | 144(60.8) | ||
Non-cardia | 1385(73.4) | 615(75.9) | 93(39.2) | ||
Tumor grade | < 0.001 | ||||
Well | 717(38.0) | 306(37.8) | 58(24.5) | ||
Poor | 1171(62.0) | 504(62.2) | 179(75.5) | ||
Stage | < 0.001 | ||||
I | 561(29.7) | 230(28.4) | 16(6.8) | ||
II | 539(28.6) | 238(29.4) | 66(27.8) | ||
III | 788(41.7) | 342(42.2) | 155(65.4) | ||
T stage | < 0.001 | ||||
T1 | 491(26.0) | 193(23.8) | 15(6.3) | ||
T2 | 258(13.7) | 141(17.4) | 25(10.6) | ||
T3 | 760(40.3) | 301(37.2) | 33(13.9) | ||
T4 | 379(20.0) | 175(21.6) | 164(69.2) | ||
N stage | < 0.001 | ||||
N0 | 825(43.7) | 337(41.6) | 54(22.8) | ||
N1 | 414(21.9) | 192(23.7) | 55(23.2) | ||
N2 | 305(16.2) | 138(17.0) | 59(24.9) | ||
N3 | 344(18.2) | 143(17.7) | 69(29.1) | ||
Size, cm | < 0.001 | ||||
< 2.7 | 570(30.2) | 241(29.8) | 40(16.9) | ||
2.7–5.3 | 763(40.4) | 303(37.4) | 113(47.7) | ||
> 5.3 | 555(29.4) | 266(32.8) | 84(35.4) | ||
LODDS | < 0.001 | ||||
LODDS1 | 933(49.4) | 383(47.3) | 67(28.3) | ||
LODDS2 | 626(33.2) | 274(33.8) | 107(45.1) | ||
LODDS3 | 329(17.4) | 153(18.9) | 63(26.6) | ||
Chemotherapy | < 0.001 | ||||
No | 1028(54.4) | 444(54.8) | 93(39.2) | ||
Yes | 860(45.6) | 366(45.2) | 144(60.8) | ||
Radiotherapy | < 0.001 | ||||
No | 1316(69.7) | 575(71.0) | 235(99.2) | ||
Yes | 572(30.3) | 235(29.0) | 2(0.8) |